While the documentation of recurrent cytogenetic/molecular abnormalities, namely t(15;17)(q22;q12), t(8;21)(q22;q22) or inv(16)(p13.1q22)/t(16;16)(p13.1;q22), is actually recognized to be sufficient, according to the WHO-2016 classification, to define a diagnosis of AML, independently of the blast percentage, the finding of NPM1 gene mutation is not currently considered to be sufficient to diagnose NPM1-mutated AML in cases with <20% blasts [5,21,69]. Here, NPM1 is linked to acute myeloid leukemia.